Calcium lactate (DrugBank: Calcium, Calcium lactate)
27 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 0 |
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
19 | Lysosomal storage disease | 0 |
46 | Malignant rheumatoid arthritis | 0 |
49 | Systemic lupus erythematosus | 0 |
51 | Scleroderma | 0 |
53 | Sjogren syndrome | 0 |
56 | Behcet disease | 0 |
68 | Ossification of the ligamentum flavum | 0 |
75 | Cushing disease | 0 |
79 | Homozygous familial hypercholesterolemia | 0 |
84 | Sarcoidosis | 0 |
93 | Primary biliary cholangitis [Primary biliary cirrhosis (~Mar 2017)] | 0 |
94 | Primary sclerosing cholangitis | 0 |
95 | Autoimmune hepatitis | 0 |
96 | Crohn disease | 0 |
97 | Ulcerative colitis | 0 |
186 | Rothmund-Thomson syndrome | 0 |
214 | Pulmonary atresia with ventricular septum defect | 0 |
215 | Tetralogy of Fallot | 0 |
222 | Primary nephrotic syndrome | 0 |
224 | Purpura nephritis | 0 |
235 | Hypoparathyroidism | 1 |
265 | Lipodystrophy | 0 |
274 | Osteogenesis Imperfecta | 0 |
298 | Hereditary pancreatitis | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-UMIN000002155 | 2009/09/01 | 06/07/2009 | Effects of falecalcitoriol on post-operative hypoparathyroidism after thyroidectomy | Postoperative hypoparathyroidism | In the first day after operation, we start administration of falecalcitriol at a dosage of 0.6ug once a day, when below the lower limit of serum calcium. If serum calcium level do not reach normal range, we escalete to 0.9ug/day.Oral calcium lactate is administered 3g/day in all enrolled patients.The dose is reduced when serum calcium and intact PTH level are maintained within normal range. If subjective symptoms such as tetany are worsen up, we start administration of calcium via DIV. | kawasaki medicak school | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 30 | Phase 3 | Japan |